Ceres Brain Therapeutics

Executive Summary

Ceres Brain Therapeutics is a privately held French biotechnology company founded in 2019, dedicated to developing small molecule therapies for cerebral diseases. Its initial focus is on Creatine Transporter Deficiency (CTD) syndrome, a rare, X-linked genetic disorder that severely impairs brain creatine uptake, leading to intellectual disability, seizures, and developmental delays. Currently, there are no approved therapies for CTD, and treatment is limited to supportive care and high-dose creatine supplementation, which is ineffective due to defective transport. Ceres is leveraging its expertise in cerebral metabolism to develop first-in-class small molecules aimed at restoring creatine transport or bypassing the deficiency. The company is in preclinical stages, with a clear unmet medical need and potential for orphan drug designation. While early-stage, the specificity of the therapeutic target and the lack of competitors in this niche position Ceres as a promising player in rare CNS diseases. Key risks include preclinical-to-clinical translation and financing for IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Series A financing or grant announcement to support IND-enabling studies40% success
• H1 2027Preclinical proof-of-concept data in animal models of CTD30% success
• Q2 2027Orphan Drug Designation (ODD) from EMA or FDA70% success